{"DataElement":{"publicId":"6069582","version":"1","preferredName":"Genomic Biomarker Test Performed Name","preferredDefinition":"Text term that represents the name of the genomic test performed for cancer.","longName":"genomic_test","context":"OCG","contextVersion":"1","DataElementConcept":{"publicId":"6066841","version":"1","preferredName":"Laboratory Procedure Genomic Biomarker Performed","preferredDefinition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._A measurable DNA or RNA characteristic that is an indicator of normal biologic processes, pathogenic processes, and/or response to therapeutic or other intervention. The definition for a genomic biomarker is not limited to human samples. A genomic biomarker could, for example, reflect: the expression of a gene; the function of a gene; the regulation of a gene. A genomic biomarker can consist of one or more deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) characteristics. The definition for a genomic biomarker does not include the measurement and characterisation of proteins or low molecular weight metabolites. DNA characteristics include, but are not limited to: single nucleotide polymorphisms (SNPs); variability of short sequence repeats; DNA modification, e.g., methylation; insertions; deletions; copy number variation; cytogenetic rearrangements, e.g., translocations, duplications, deletions or inversions. RNA characteristics include, but are not limited to: RNA sequence; RNA expression levels; RNA processing, e.g., splicing and editing; microRNA levels (ICH Draft Consensus Guideline E15)._Executed and carried through to completion.","longName":"2543047v1.0:6066839v1.0","context":"OCG","contextVersion":"1","ObjectClass":{"publicId":"2543047","version":"1","preferredName":"Test","preferredDefinition":"A procedure for critical evaluation; a means of determining the presence, quality, or truth of something.","longName":"C25294","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Laboratory Procedure","conceptCode":"C25294","definition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2262D258-9F2F-4D98-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-11-16","modifiedBy":"ONEDATA","dateModified":"2006-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6066839","version":"1","preferredName":"Genomic Biomarker Performed","preferredDefinition":"A measurable DNA or RNA characteristic that is an indicator of normal biologic processes, pathogenic processes, and/or response to therapeutic or other intervention. The definition for a genomic biomarker is not limited to human samples. A genomic biomarker could, for example, reflect: the expression of a gene; the function of a gene; the regulation of a gene. A genomic biomarker can consist of one or more deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) characteristics. The definition for a genomic biomarker does not include the measurement and characterisation of proteins or low molecular weight metabolites. DNA characteristics include, but are not limited to: single nucleotide polymorphisms (SNPs); variability of short sequence repeats; DNA modification, e.g., methylation; insertions; deletions; copy number variation; cytogenetic rearrangements, e.g., translocations, duplications, deletions or inversions. RNA characteristics include, but are not limited to: RNA sequence; RNA expression levels; RNA processing, e.g., splicing and editing; microRNA levels (ICH Draft Consensus Guideline E15).:Executed and carried through to completion.","longName":"C68753:C38000","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Genomic Biomarker","conceptCode":"C68753","definition":"A measurable DNA or RNA characteristic that is an indicator of normal biologic processes, pathogenic processes, and/or response to therapeutic or other intervention. The definition for a genomic biomarker is not limited to human samples. A genomic biomarker could, for example, reflect: the expression of a gene; the function of a gene; the regulation of a gene. A genomic biomarker can consist of one or more deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) characteristics. The definition for a genomic biomarker does not include the measurement and characterisation of proteins or low molecular weight metabolites. DNA characteristics include, but are not limited to: single nucleotide polymorphisms (SNPs); variability of short sequence repeats; DNA modification, e.g., methylation; insertions; deletions; copy number variation; cytogenetic rearrangements, e.g., translocations, duplications, deletions or inversions. RNA characteristics include, but are not limited to: RNA sequence; RNA expression levels; RNA processing, e.g., splicing and editing; microRNA levels (ICH Draft Consensus Guideline E15).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Performed","conceptCode":"C38000","definition":"Executed and carried through to completion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65073354-0178-7BCE-E053-F662850A3C77","latestVersionIndicator":"Yes","beginDate":"2018-02-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-02-12","modifiedBy":"ONEDATA","dateModified":"2018-02-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"65073354-0189-7BCE-E053-F662850A3C77","latestVersionIndicator":"Yes","beginDate":"2018-02-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-02-12","modifiedBy":"COOPERM","dateModified":"2018-03-05","changeDescription":"Created for Breast CDE spreadsheet. 1.31.18 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6066856","version":"1","preferredName":"Genetic Biomarker Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"6066856v1.0","context":"OCG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"120","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other (specify)","valueDescription":"Specify Other","ValueMeaning":{"publicId":"4888051","version":"1","preferredName":"Specify Other","longName":"4888051","preferredDefinition":"Be specific about something; define clearly.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"195A90B1-87F5-D292-E050-BB89AD432B03","latestVersionIndicator":"Yes","beginDate":"2015-06-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-06-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65078E4E-31E6-58CC-E053-F662850A6A03","beginDate":"2018-02-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-02-12","modifiedBy":"ONEDATA","dateModified":"2018-02-12","deletedIndicator":"No"},{"value":"MammaPrint","valueDescription":"MammaPrint","ValueMeaning":{"publicId":"6066857","version":"1","preferredName":"MammaPrint","longName":"6066857","preferredDefinition":"An in vitro molecular diagnostic test that uses gene expression profiling to analyze gene activity within a breast cancer tumor sample. It looks at the activity of 70 genes and is useful in assessing the likelihood of metastasis and recurrence.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MammaPrint","conceptCode":"C84345","definition":"An in vitro molecular diagnostic test that uses gene expression profiling to analyze gene activity within a breast cancer tumor sample. It looks at the activity of 70 genes and is useful in assessing the likelihood of metastasis and recurrence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65078E4E-31F1-58CC-E053-F662850A6A03","latestVersionIndicator":"Yes","beginDate":"2018-02-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-02-12","modifiedBy":"ONEDATA","dateModified":"2018-02-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65078E4E-320A-58CC-E053-F662850A6A03","beginDate":"2018-02-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-02-12","modifiedBy":"ONEDATA","dateModified":"2018-02-12","deletedIndicator":"No"},{"value":"Oncotype","valueDescription":"Oncotype DX Breast Cancer Assay","ValueMeaning":{"publicId":"6066858","version":"1","preferredName":"Oncotype DX Breast Cancer Assay","longName":"6066858","preferredDefinition":"A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oncotype DX Breast Cancer Assay","conceptCode":"C52159","definition":"A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65078E4E-3214-58CC-E053-F662850A6A03","latestVersionIndicator":"Yes","beginDate":"2018-02-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-02-12","modifiedBy":"ONEDATA","dateModified":"2018-02-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65078E4E-322D-58CC-E053-F662850A6A03","beginDate":"2018-02-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-02-12","modifiedBy":"ONEDATA","dateModified":"2018-02-12","deletedIndicator":"No"},{"value":"ProMark","valueDescription":"ProMark","ValueMeaning":{"publicId":"6815705","version":"1","preferredName":"ProMark","longName":"6815705","preferredDefinition":"ProMark Proteomic Prognostic Test for Prostate Cancer","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8D47B830-8016-0D52-E053-F662850AC806","latestVersionIndicator":"Yes","beginDate":"2019-07-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-09","modifiedBy":"ONEDATA","dateModified":"2019-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8D47B830-802F-0D52-E053-F662850AC806","beginDate":"2019-07-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-09","modifiedBy":"ONEDATA","dateModified":"2019-07-09","deletedIndicator":"No"},{"value":"Prolaris","valueDescription":"Prolaris Prostate Cancer Testing","ValueMeaning":{"publicId":"6815707","version":"1","preferredName":"Prolaris Prostate Cancer Testing","longName":"6815707","preferredDefinition":"A proprietary prognostic test which directly measures tumor cell growth characteristics for stratifying the risk of disease progression in prostate cancer patients. It provides a measure of the aggressiveness of an individual's prostate cancer and predicts disease-specific mortality.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prolaris Prostate Cancer Testing","conceptCode":"C150175","definition":"A proprietary prognostic test which directly measures tumor cell growth characteristics for stratifying the risk of disease progression in prostate cancer patients. It provides a measure of the aggressiveness of an individual's prostate cancer and predicts disease-specific mortality.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8D47B830-803C-0D52-E053-F662850AC806","latestVersionIndicator":"Yes","beginDate":"2019-07-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-09","modifiedBy":"ONEDATA","dateModified":"2019-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8D47B830-8055-0D52-E053-F662850AC806","beginDate":"2019-07-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-09","modifiedBy":"ONEDATA","dateModified":"2019-07-09","deletedIndicator":"No"},{"value":"Oncotype Dx Prostate","valueDescription":"Oncotype DX Genomic Prostate Score","ValueMeaning":{"publicId":"6035476","version":"1","preferredName":"Oncotype DX Genomic Prostate Score","longName":"6035476","preferredDefinition":"A proprietary multi-gene assay that analyzes expression of 17 genes across four genetic pathways to predict prostate cancer aggressiveness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oncotype DX Genomic Prostate Score","conceptCode":"C142186","definition":"A proprietary multi-gene assay that analyzes expression of 17 genes across four genetic pathways to predict prostate cancer aggressiveness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F844ABC-A652-63EB-E053-F662850AF0A4","latestVersionIndicator":"Yes","beginDate":"2017-12-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-12-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8D47B830-8069-0D52-E053-F662850AC806","beginDate":"2019-07-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-09","modifiedBy":"ONEDATA","dateModified":"2019-07-09","deletedIndicator":"No"},{"value":"Decipher","valueDescription":"Decipher Prostate Cancer Test","ValueMeaning":{"publicId":"6035475","version":"1","preferredName":"Decipher Prostate Cancer Test","longName":"6035475","preferredDefinition":"A proprietary genetic test that evaluates a prostate cancer tumor for its potential for metastasis. Decipher measures the expression levels of 22 RNA biomarkers involved in multiple biological pathways that are associated with metastasis and aggressive prostate cancer to classify tumors as high, average, or low risk of metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Decipher Prostate Cancer Test","conceptCode":"C128181","definition":"A proprietary genetic test that evaluates a prostate cancer tumor for its potential for metastasis. Decipher measures the expression levels of 22 RNA biomarkers involved in multiple biological pathways that are associated with metastasis and aggressive prostate cancer to classify tumors as high, average, or low risk of metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F844ABC-A62D-63EB-E053-F662850AF0A4","latestVersionIndicator":"Yes","beginDate":"2017-12-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-12-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8D47B830-807E-0D52-E053-F662850AC806","beginDate":"2019-07-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-09","modifiedBy":"ONEDATA","dateModified":"2019-07-09","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2229718","version":"1","preferredName":"Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F6EF4E2B-76AE-72C1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-05-16","modifiedBy":"ONEDATA","dateModified":"2005-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"65078E4E-31CE-58CC-E053-F662850A6A03","latestVersionIndicator":"Yes","beginDate":"2018-02-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-02-12","modifiedBy":"COOPERM","dateModified":"2019-07-09","changeDescription":"Created for Breast CDE spreadsheet. 1.31.18 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5806857","version":"1","longName":"HCMI (Human Cancer Models Initiative)","context":"OCG","ClassificationSchemeItems":[{"publicId":"10000009","version":"1","longName":"Breast","context":"OCG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"What genomic test was perform","type":"Preferred Question Text","description":"What genomic test was performed?","url":null,"context":"OCG"}],"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"651B0894-7C7C-343D-E053-F662850AF7A1","latestVersionIndicator":"Yes","beginDate":"2018-02-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-02-13","modifiedBy":"COOPERM","dateModified":"2018-03-05","changeDescription":"Created for Breast CDE spreadsheet. 1.31.18 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}